Europe

Novartis, Dr. Vasella cancel non-compete agreement

Wednesday, February 20, 2013 09:29 AM

The Novartis board of directors and Dr. Daniel Vasella, chairman of the company’s board, have agreed to cancel Vasella’s non-compete agreement with Novartis and all related conditional compensation. The agreement was to take effect after Vasella steps down as chairman of the board on February 22, 2013.

More... »

Cromsource further expands Polish operations

Friday, February 15, 2013 11:17 AM

Cromsource, an international full service CRO, has opened of a new office building in Warsaw, Poland, and has completed moving key company services to the new location.

More... »

New IMI projects to revitalize antibiotic development

Wednesday, February 13, 2013 02:04 PM

The Innovative Medicines Initiative (IMI), the world’s largest public-private partnership in health care, has launched the first two projects under its antimicrobial resistance research program, New Drugs for Bad Bugs (ND4BB). The new projects, COMBACTE (Combating Bacterial Resistance in Europe) and TRANSLOCATION (Molecular basis of the bacterial cell wall permeability), are set to revitalize antibiotic development by promoting greater collaboration within the entire antibiotic development community, and by tackling key challenges to the development of new medicines.

More... »

Critical Pharma completes second trial on CP024 intranasal growth hormone

Wednesday, February 13, 2013 12:13 PM

Critical Pharmaceuticals, a Nottingham, U.K.-based biotechnology company, has successfully completed a second clinical study on its CP024 growth hormone nasal spray.

More... »

e-Therapeutics to raise $62 million for cancer drug, network pharmacology platform

Monday, February 11, 2013 02:08 PM

Drug discovery and development company e-Therapeutics has proposed raising $62 million through an issue of new ordinary shares to existing and new institutional investors.

More... »

$262M Pan-European drug discovery platform launched

Friday, February 8, 2013 10:48 AM

The European Lead Factory, a novel platform for innovative drug discovery, was launched Feb. 7 by an international consortium of 30 partners. The partnership, the first of its kind, is supported by the Innovative Medicines Initiative (IMI) and creates opportunities for the discovery of new medicines by providing public partners with an “industry-like” discovery platform to translate cutting-edge academic research into high-quality drug lead molecules on a scale and speed that was not possible previously.

More... »

Recipharm appoints Lennernäs to operating board

Wednesday, February 6, 2013 12:38 PM

Recipharm, a contract development and manufacturing organization based in Sweden, has appointed Dr. Hans Lennernäs to the operating board of Recipharm Pharmaceutical Development.

More... »

British public wants to crowdfund innovative companies

Tuesday, February 5, 2013 08:00 AM

The British public wants the opportunity to crowdfund innovative British companies. That is the message from a YouGov survey commissioned by the BioIndustry Association (BIA) which shows that nearly nine out of 10 U.K. adults who expressed a preference agree that the general public should be provided with the opportunity to invest modest sums of money, if they wish to, into funds that will be targeted towards innovative companies.

More... »

Patheon increases investment in Milton Park, U.K. facility

Monday, February 4, 2013 12:27 PM

Patheon, a provider of contract development and commercial manufacturing services, has announced plans for additional investment in its Milton Park facility. Located in Oxfordshire, U.K., Milton Park is a dedicated pharmaceutical development services facility focused on early development projects.

More... »

Domain grants Prexton exclusive license and development of mGluR4 PAMs for Parkinson’s

Friday, January 25, 2013 11:01 AM

Domain Therapeutics, a French biopharmaceutical company, has granted Switzerland–based Prexton Therapeutics an exclusive option to license and develop metabotropic glutamate receptor 4 (mGluR4) Positive Allosteric Modulator (PAM) drugs targeting Parkinson’s disease.

More... »